Literature DB >> 22850770

DSM-5 and clinical trials in psychiatry: challenges to come?

Florence Butlen-Ducuing1, Manuel Haas, Luca Pani, Barbara van Zwieten-Boot, Karl Broich.   

Abstract

The publication of the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in 2013 raises important questions for clinical trials and associated regulatory decisions on new drugs for psychiatric disorders.

Entities:  

Mesh：

Year:  2012        PMID： 22850770     DOI： 10.1038/nrd3811

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

1.  DSM-5: how reliable is reliable enough?

Authors:  Helena Chmura Kraemer; David J Kupfer; Diana E Clarke; William E Narrow; Darrel A Regier
Journal:  Am J Psychiatry       Date:  2012-01       Impact factor: 18.112

2.  Rethinking mental illness.

Authors:  Thomas R Insel; Philip S Wang
Journal:  JAMA       Date:  2010-05-19       Impact factor: 56.272

Review 3.  DSM-5 proposals for mood disorders: a cost-benefit analysis.

Authors:  Michael B First
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

4.  DSM-5: proposed changes to depressive disorders.

Authors:  Jerome C Wakefield
Journal:  Curr Med Res Opin       Date:  2012-02-22       Impact factor: 2.580

Review 5.  Dimensional approaches to psychiatric classification: refining the research agenda for DSM-V: an introduction.

Authors:  Darrel A Regier
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035
  5 in total
  2 in total

1.  Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Authors:  Elsa Gilbert; Chantal Mérette; Valérie Jomphe; Claudia Emond; Nancie Rouleau; Roch-Hugo Bouchard; Marc-André Roy; Thomas Paccalet; Michel Maziade
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-31       Impact factor: 5.270

2.  Trends in US pediatric mental health clinical trials: An analysis of ClinicalTrials.gov from 2007-2018.

Authors:  Joshua R Wortzel; Brandon E Turner; Brannon T Weeks; Christopher Fragassi; Virginia Ramos; Thanh Truong; Desiree Li; Omar Sahak; Thomas G O'Connor
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.